BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Takai T, Takaya T, Nakano M, Akutsu H, Nakagawa A, Aimoto S, Nagai K, Ikegami T. Orexin-A is composed of a highly conservedC-terminal and a specific, hydrophilicN-terminal region, revealing the structural basis of specific recognition by the orexin-1 receptor. J Pept Sci 2006;12:443-54. [DOI: 10.1002/psc.747] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Duffet L, Kosar S, Panniello M, Viberti B, Bracey E, Zych AD, Radoux-Mergault A, Zhou X, Dernic J, Ravotto L, Tsai YC, Figueiredo M, Tyagarajan SK, Weber B, Stoeber M, Gogolla N, Schmidt MH, Adamantidis AR, Fellin T, Burdakov D, Patriarchi T. A genetically encoded sensor for in vivo imaging of orexin neuropeptides. Nat Methods 2022;19:231-41. [PMID: 35145320 DOI: 10.1038/s41592-021-01390-2] [Reference Citation Analysis]
2 Malherbe P, Roche O, Marcuz A, Kratzeisen C, Wettstein JG, Bissantz C. Mapping the Binding Pocket of Dual Antagonist Almorexant to Human Orexin 1 and Orexin 2 Receptors: Comparison with the Selective OX 1 Antagonist SB-674042 and the Selective OX 2 Antagonist N -Ethyl-2-[(6-methoxy-pyridin-3-yl)-(toluene-2-sulfonyl)-amino]- N -pyridin-3-ylmethyl-acetamide (EMPA). Mol Pharmacol 2010;78:81-93. [DOI: 10.1124/mol.110.064584] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
3 Haack M, Beck-sickinger AG. Multiple Peptide Synthesis to Identify Bioactive Hormone Structures. In: Bräse S, editor. Combinatorial Chemistry on Solid Supports. Berlin: Springer Berlin Heidelberg; 2007. pp. 243-88. [DOI: 10.1007/128_2006_106] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Yshii LM, Souza GH, Camargo EA, Eberlin MN, Ribela MTC, Muscará MN, Hyslop S, Costa SK. Characterization of the mechanisms underlying the inflammatory response to Polistes lanio lanio (paper wasp) venom in mouse dorsal skin. Toxicon 2009;53:42-52. [DOI: 10.1016/j.toxicon.2008.10.006] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
5 Ramser A, Dridi S. Avian Orexin: Feed Intake Regulator or Something Else? Veterinary Sciences 2022;9:112. [DOI: 10.3390/vetsci9030112] [Reference Citation Analysis]
6 Hagen J, Lyon W, Chushak Y, Tomczak M, Naik R, Stone M, Kelley-Loughnane N. Detection of orexin A neuropeptide in biological fluids using a zinc oxide field effect transistor. ACS Chem Neurosci 2013;4:444-53. [PMID: 23509980 DOI: 10.1021/cn300159e] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
7 Sakai N, Matsumura M, Lin L, Mignot E, Nishino S. HPLC analysis of CSF hypocretin-1 in type 1 and 2 narcolepsy. Sci Rep 2019;9:477. [PMID: 30679597 DOI: 10.1038/s41598-018-36942-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
8 Heifetz A, Barker O, Morris GB, Law RJ, Slack M, Biggin PC. Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis. Biochemistry 2013;52:8246-60. [PMID: 24144388 DOI: 10.1021/bi401119m] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
9 Guerreiro S, Florence C, Rousseau E, Hamadat S, Hirsch EC, Michel PP. The Sleep-Modulating Peptide Orexin-B Protects Midbrain Dopamine Neurons from Degeneration, Alone or in Cooperation with Nicotine. Mol Pharmacol 2015;87:525-32. [DOI: 10.1124/mol.114.095703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
10 Liu M, Min T, Zhang H, Liu Y, Wang Z. Pharmacological Characteristics of Porcine Orexin 2 Receptor and Mutants. Front Endocrinol (Lausanne) 2020;11:132. [PMID: 32296386 DOI: 10.3389/fendo.2020.00132] [Reference Citation Analysis]
11 Kukkonen JP. Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol Cell Physiol 2013;304:C2-32. [PMID: 23034387 DOI: 10.1152/ajpcell.00227.2012] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
12 Malherbe P, Borroni E, Pinard E, Wettstein JG, Knoflach F. Biochemical and Electrophysiological Characterization of Almorexant, a Dual Orexin 1 Receptor (OX 1 )/Orexin 2 Receptor (OX 2 ) Antagonist: Comparison with Selective OX 1 and OX 2 Antagonists. Mol Pharmacol 2009;76:618-31. [DOI: 10.1124/mol.109.055152] [Cited by in Crossref: 54] [Cited by in F6Publishing: 58] [Article Influence: 4.2] [Reference Citation Analysis]
13 Palomer A, Príncep M, Guglietta A. Chapter 5 Recent Advances in the Treatment of Insomnia. Annual Reports in Medicinal Chemistry Volume 42. Elsevier; 2007. pp. 63-80. [DOI: 10.1016/s0065-7743(07)42005-x] [Cited by in Crossref: 7] [Article Influence: 0.5] [Reference Citation Analysis]
14 Karhu L, Weisell J, Turunen PM, Leino TO, Pätsi H, Xhaard H, Kukkonen JP, Wallén EAA. Stapled truncated orexin peptides as orexin receptor agonists. Peptides 2018;102:54-60. [PMID: 29475074 DOI: 10.1016/j.peptides.2018.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
15 Ohno K, Sakurai T. Orexin neuronal circuitry: role in the regulation of sleep and wakefulness. Front Neuroendocrinol 2008;29:70-87. [PMID: 17910982 DOI: 10.1016/j.yfrne.2007.08.001] [Cited by in Crossref: 178] [Cited by in F6Publishing: 162] [Article Influence: 11.9] [Reference Citation Analysis]
16 German NA, Decker AM, Gilmour BP, Thomas BF, Zhang Y. Truncated Orexin Peptides: Structure-Activity Relationship Studies. ACS Med Chem Lett 2013;4:1224-7. [PMID: 24707347 DOI: 10.1021/ml400333a] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
17 Putula J, Pihlajamaa T, Kukkonen JP. Calcium affects OX1 orexin (hypocretin) receptor responses by modifying both orexin binding and the signal transduction machinery. Br J Pharmacol 2014;171:5816-28. [PMID: 25132134 DOI: 10.1111/bph.12883] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
18 Karhu L, Turku A, Xhaard H. Modeling of the OX1R-orexin-A complex suggests two alternative binding modes. BMC Struct Biol 2015;15:9. [PMID: 25957175 DOI: 10.1186/s12900-015-0036-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
19 Plaza-Zabala A, Maldonado R, Berrendero F. The hypocretin/orexin system: implications for drug reward and relapse. Mol Neurobiol 2012;45:424-39. [PMID: 22430644 DOI: 10.1007/s12035-012-8255-z] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 3.5] [Reference Citation Analysis]
20 Ohtani S, Fujita S, Hasegawa K, Tsuda H, Tonogi M, Kobayashi M. Relationship between the fluorescence intensity of rhodamine-labeled orexin A and the calcium responses in cortical neurons: An in vivo two-photon calcium imaging study. J Pharmacol Sci 2018;138:76-82. [PMID: 30293961 DOI: 10.1016/j.jphs.2018.09.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
21 Karhu L, Magarkar A, Bunker A, Xhaard H. Determinants of Orexin Receptor Binding and Activation-A Molecular Dynamics Study. J Phys Chem B 2019;123:2609-22. [PMID: 30786708 DOI: 10.1021/acs.jpcb.8b10220] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]